Efficacy and Safety of Gemcitabine-oxaliplatin Combined with Huachansu in Patients with Advanced Gallbladder Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2008 Sep 9

PMID 18777599

Citations 42

Authors

Tian-Jie Qin

Xin-Han Zhao

Jun Yun

Ling-Xiao Zhang

Zhi-Ping Ruan

Bo-Rong Pan

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the efficacy and safety of gemcitabine-oxaliplatin (GEMOX) combined with huachansu (cinobufagin) injection treatment in patients with locally advanced or metastatic gallbladder carcinoma (GBC), and to assess the quality of life (QOL) of such patients.

Methods: Twenty-five patients with locally advanced or metastatic GBC were treated with intravenous gemcitabine (1000 mg/m2) over 30 min on days 1 and 8, 2 h infusion of oxaliplatin (120 mg/ m2) on day 1, and 2-3 h infusion of huachansu (20 mL/ m2) on days -3-11, every 3-4 wk. Treatment was continued until occurrence of unacceptable toxicity or disease progression. QOL of patients was assessed by the EORTC QLQ-C30 at baseline, at the end of the first, third and sixth chemotherapy cycles, and 1 mo after the treatment.

Results: Among the 25 patients with a median age of 64 years (range 42-78 years), 23 were evaluable in the study. A total of 137 cycles of therapy were performed and the median cycle was 5 (range 1-8) per patient. Out of the 23 patients whose response could be evaluated, 8 partial responses (PR) were observed (34.8%), while 7 patients (30.4%) demonstrated a stable disease (SD). The disease control rate was 65.2%. Progression of cancer was observed in 8 (34.8%) patients. The median progression-free and overall survival time was 5.8 mo (95% CI: 4.5-7.1 mo) and 10.5 mo, respectively. The therapy was well tolerated, with moderate myelosuppression as the main toxicity. Anemia grade 2 was seen in 16.0%, neutropenia grade 3 in 8.0% and thrombocytopenia grade 3 in 24.0% of patients, respectively. Non-hematologic toxicity ranged from mild to moderate. No death occurred due to toxicity. The QOL of patients was improved after chemotherapy, and the scores of QOL were increased by 10 to 20 points.

Conclusion: GEMOX combined with huachansu (cinobufagin) injection is well tolerated, effective, thus improving the QOL of patients with advanced GBC.

Citing Articles

Material basis revelation of anti-hepatoma effect of Huachansu (Cinobufacini) through down-regulation of thymidylate synthase.

Wu Q, Chen Q, Yang J, Zhang J, Yang A Chin Herb Med. 2025; 17(1):127-138.

PMID: 39949800 PMC: 11814253. DOI: 10.1016/j.chmed.2024.04.002.

Harnessing Arsenic Derivatives and Natural Agents for Enhanced Glioblastoma Therapy.

Yuan B, Kikuchi H Cells. 2025; 13(24.

PMID: 39768226 PMC: 11674460. DOI: 10.3390/cells13242138.

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.

Wu J, Tang G, Cheng C, Yeerken R, Chan Y, Fu Z Mol Cancer. 2024; 23(1):218.

PMID: 39354529 PMC: 11443773. DOI: 10.1186/s12943-024-02136-2.

Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression.

Kwantwi L, Tandoh T Clin Transl Oncol. 2024; .

PMID: 39269597 DOI: 10.1007/s12094-024-03723-x.

Bufalin Suppresses Head and Neck Cancer Development by Modulating Immune Responses and Targeting the β-Catenin Signaling Pathway.

Mhaidly N, Barake N, Trelcat A, Journe F, Saussez S, Descamps G Cancers (Basel). 2024; 16(15).

PMID: 39123466 PMC: 11311268. DOI: 10.3390/cancers16152739.

References

He X, Tang J, Qiao A, Wang G, Jiang M, Liu R . Cytotoxic biotransformed products from cinobufagin by Mucor spinosus and Aspergillus Niger. Steroids. 2006; 71(5):392-402. DOI: 10.1016/j.steroids.2005.12.003. View

Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16(1):139-44. DOI: 10.1200/JCO.1998.16.1.139. View

Nehls O, Oettle H, Hartmann J, Hofheinz R, Hass H, Horger M . Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008; 98(2):309-15. PMC: 2361467. DOI: 10.1038/sj.bjc.6604178. View

Philip P, Mahoney M, Allmer C, Thomas J, Pitot H, Kim G . Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006; 24(19):3069-74. DOI: 10.1200/JCO.2005.05.3579. View

Gallardo J, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C . A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol. 2002; 12(10):1403-6. DOI: 10.1023/a:1012543223020. View

Ye M, Guo H, Guo H, Han J, Guo D . Simultaneous determination of cytotoxic bufadienolides in the Chinese medicine ChanSu by high-performance liquid chromatography coupled with photodiode array and mass spectrometry detections. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 838(2):86-95. DOI: 10.1016/j.jchromb.2006.04.042. View

von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid R, Eckel F . Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer. 2005; 5:61. PMC: 1180427. DOI: 10.1186/1471-2407-5-61. View

Ye M, Qu G, Guo H, Guo D . Specific 12 beta-hydroxylation of cinobufagin by filamentous fungi. Appl Environ Microbiol. 2004; 70(6):3521-7. PMC: 427727. DOI: 10.1128/AEM.70.6.3521-3527.2004. View

Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D . Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004; 15(9):1339-43. DOI: 10.1093/annonc/mdh351. View

10.

Yang D, He J, Zhang J, Wang Z . Expression of angiostatin cDNA in human gallbladder carcinoma cell line GBC-SD and its effect on endothelial proliferation and growth. World J Gastroenterol. 2006; 12(17):2762-6. PMC: 4130987. DOI: 10.3748/wjg.v12.i17.2762. View

11.

Ma X, Xin X, Liu K, Han J, Guo D . Microbial transformation of cinobufagin by Syncephalastrum racemosum. J Nat Prod. 2008; 71(7):1268-70. DOI: 10.1021/np800210a. View

12.

Thongprasert S, Napapan S, Charoentum C, Moonprakan S . Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005; 16(2):279-81. DOI: 10.1093/annonc/mdi046. View

13.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

14.

Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C . Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest. 2003; 21(5):690-4. DOI: 10.1081/cnv-120023767. View

15.

Hsu C, Shen Y, Yang C, Yeh K, Lu Y, Hsu C . Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer. 2004; 90(9):1715-9. PMC: 2409758. DOI: 10.1038/sj.bjc.6601796. View

16.

Dai L, Wang Z, Gao H, Jiang X, Ding G . [Determination of bufothionine in skin of Bufo bufo gargarizans and Huachansu injection]. Zhongguo Zhong Yao Za Zhi. 2007; 32(3):224-6. View

17.

Zhang P, Cui Z, Liu Y, Wang D, Liu N, Yoshikawa M . Quality evaluation of traditional Chinese drug toad venom from different origins through a simultaneous determination of bufogenins and indole alkaloids by HPLC. Chem Pharm Bull (Tokyo). 2005; 53(12):1582-6. DOI: 10.1248/cpb.53.1582. View

18.

Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D . Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004; 22(2):193-8. DOI: 10.1023/B:DRUG.0000011797.09549.53. View

19.

Park J, Oh S, Kim S, Kwon H, Kim J, Jin-Kim H . Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol. 2005; 35(2):68-73. DOI: 10.1093/jjco/hyi021. View

20.

Murad A, Guimaraes R, Aragao B, Rodrigues V, Scalabrini-Neto A, Padua C . Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol. 2003; 26(2):151-4. DOI: 10.1097/00000421-200304000-00010. View